CNTX Context Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CNTX

Price (delayed)

$2.025

Market cap

$186.06M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.42

Enterprise value

$131.81M

?
Relative Growth: Rel. Growth: 2
Relative Strength: Rel. Strength: 92
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 2

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a ...

Highlights
CNTX's debt has soared by 152% since the previous quarter and by 46% year-on-year
The quick ratio has shrunk by 82% YoY
Sector: Healthcare
Industry: Biotechnology
Website: https://www.contexttherapeutics.com
Peers: VRTX NTLA CRSP EDIT

Key stats

What are the main financial stats of CNTX

CNTX stock price

How has the Context Therapeutics stock price performed over time
Intraday
-1.22%
1 week
-28.45%
1 month
-11.96%
1 year
251.99%
YTD
37.76%
QTD
-22.71%

Financial performance

How have Context Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$43.17M
Net income
-$40.23M
Gross margin
N/A
Net margin
N/A
Context Therapeutics's net income has decreased by 46% YoY and by 11% from the previous quarter
CNTX's operating income is down by 36% year-on-year and by 9% since the previous quarter

Price vs fundamentals

How does CNTX's price correlate with its fundamentals

Growth

What is Context Therapeutics's growth rate over time

Valuation

What is Context Therapeutics stock price valuation
P/E
N/A
P/B
3.56
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
CNTX's EPS is down by 35% year-on-year and by 11% since the previous quarter
CNTX's P/B is 178% higher than its 5-year quarterly average of 1.3 and 64% higher than its last 4 quarters average of 2.2
The equity is down by 43% year-on-year and by 14% since the previous quarter

Efficiency

How efficient is Context Therapeutics business performance
CNTX's ROE has dropped by 101% year-on-year and by 28% since the previous quarter
The ROA has shrunk by 88% YoY and by 24% QoQ

Dividends

What is CNTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CNTX.

Financial health

How did Context Therapeutics financials performed over time
The quick ratio has shrunk by 82% YoY
The current ratio has dropped by 82% year-on-year but it is up by 5% since the previous quarter
CNTX's debt is 99% smaller than its equity
CNTX's debt has soared by 152% since the previous quarter and by 46% year-on-year
The equity is down by 43% year-on-year and by 14% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.